| Dr Melinda Ann Crockett-maples, MD | |
|
1235 E Cherokee St, Springfield, MO 65804-2203 | |
| (417) 820-2600 | |
| Not Available |
| Full Name | Dr Melinda Ann Crockett-maples |
|---|---|
| Gender | Female |
| Speciality | Hospitalist |
| Experience | 34 Years |
| Location | 1235 E Cherokee St, Springfield, Missouri |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154485993 | NPI | - | NPPES |
| 110228938 | Other | MO | RAILROAD MEDICARE |
| 505773408 | Medicaid | MO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 103374 (Missouri) | Primary |
| 207R00000X | Internal Medicine | 103374 (Missouri) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mercy Hospital Springfield | Springfield, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mercy Clinic Springfield Communities | 7416865845 | 922 |
News Archive
EcoNugenics® is proud to introduce BreastDefend™, a new nutraceutical compound formulated specifically to promote and maintain breast health. Physician-formulated BreastDefend is crafted from eight exclusive, clinically tested compounds, including scientifically supported nutrients, herbs, and medicinal mushrooms.
Highland Therapeutics, Inc., a specialty pharmaceutical company based in the MaRS Discovery District in Toronto, today announced that its wholly owned subsidiary has generated positive Phase-1 results for HLD-200 - a novel formulation of methylphenidate being developed to treat the symptoms associated with Attention-Deficit/Hyperactivity Disorder.
Losing as little as 30 minutes of sleep per day on weekdays can have long-term consequences for body weight and metabolism, a new study finds. The results will be presented Thursday, March 5, at ENDO 2015, the annual meeting of the Endocrine Society in San Diego.
Bayer Inc. and Teva Canada Limited today announced they have entered an agreement regarding Bayer's Adalat XL (nifedipine) 20, 30 and 60 mg product. Effective immediately, Bayer Inc. will supply Adalat XL exclusively to Teva Canada Limited and Teva Canada Limited will become the sole distributor in Canada of brand name Adalat XL product.
Johns Hopkins Kimmel Cancer Center researchers say preliminary studies show that a vaccine made with leukemia cells may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Imatinib mesylate (Gleevec).
› Verified 1 days ago
| Entity Name | Mercy Clinic Springfield Communities |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245277631 PECOS PAC ID: 7416865845 Enrollment ID: O20031104000060 |
News Archive
EcoNugenics® is proud to introduce BreastDefend™, a new nutraceutical compound formulated specifically to promote and maintain breast health. Physician-formulated BreastDefend is crafted from eight exclusive, clinically tested compounds, including scientifically supported nutrients, herbs, and medicinal mushrooms.
Highland Therapeutics, Inc., a specialty pharmaceutical company based in the MaRS Discovery District in Toronto, today announced that its wholly owned subsidiary has generated positive Phase-1 results for HLD-200 - a novel formulation of methylphenidate being developed to treat the symptoms associated with Attention-Deficit/Hyperactivity Disorder.
Losing as little as 30 minutes of sleep per day on weekdays can have long-term consequences for body weight and metabolism, a new study finds. The results will be presented Thursday, March 5, at ENDO 2015, the annual meeting of the Endocrine Society in San Diego.
Bayer Inc. and Teva Canada Limited today announced they have entered an agreement regarding Bayer's Adalat XL (nifedipine) 20, 30 and 60 mg product. Effective immediately, Bayer Inc. will supply Adalat XL exclusively to Teva Canada Limited and Teva Canada Limited will become the sole distributor in Canada of brand name Adalat XL product.
Johns Hopkins Kimmel Cancer Center researchers say preliminary studies show that a vaccine made with leukemia cells may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Imatinib mesylate (Gleevec).
› Verified 1 days ago
| Entity Name | Mercy Clinic Springfield Communities |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972771657 PECOS PAC ID: 7416865845 Enrollment ID: O20031218000354 |
News Archive
EcoNugenics® is proud to introduce BreastDefend™, a new nutraceutical compound formulated specifically to promote and maintain breast health. Physician-formulated BreastDefend is crafted from eight exclusive, clinically tested compounds, including scientifically supported nutrients, herbs, and medicinal mushrooms.
Highland Therapeutics, Inc., a specialty pharmaceutical company based in the MaRS Discovery District in Toronto, today announced that its wholly owned subsidiary has generated positive Phase-1 results for HLD-200 - a novel formulation of methylphenidate being developed to treat the symptoms associated with Attention-Deficit/Hyperactivity Disorder.
Losing as little as 30 minutes of sleep per day on weekdays can have long-term consequences for body weight and metabolism, a new study finds. The results will be presented Thursday, March 5, at ENDO 2015, the annual meeting of the Endocrine Society in San Diego.
Bayer Inc. and Teva Canada Limited today announced they have entered an agreement regarding Bayer's Adalat XL (nifedipine) 20, 30 and 60 mg product. Effective immediately, Bayer Inc. will supply Adalat XL exclusively to Teva Canada Limited and Teva Canada Limited will become the sole distributor in Canada of brand name Adalat XL product.
Johns Hopkins Kimmel Cancer Center researchers say preliminary studies show that a vaccine made with leukemia cells may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Imatinib mesylate (Gleevec).
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Melinda Ann Crockett-maples, MD 1235 E Cherokee St, Springfield, MO 65804-2203 Ph: (417) 820-2600 | Dr Melinda Ann Crockett-maples, MD 1235 E Cherokee St, Springfield, MO 65804-2203 Ph: (417) 820-2600 |
News Archive
EcoNugenics® is proud to introduce BreastDefend™, a new nutraceutical compound formulated specifically to promote and maintain breast health. Physician-formulated BreastDefend is crafted from eight exclusive, clinically tested compounds, including scientifically supported nutrients, herbs, and medicinal mushrooms.
Highland Therapeutics, Inc., a specialty pharmaceutical company based in the MaRS Discovery District in Toronto, today announced that its wholly owned subsidiary has generated positive Phase-1 results for HLD-200 - a novel formulation of methylphenidate being developed to treat the symptoms associated with Attention-Deficit/Hyperactivity Disorder.
Losing as little as 30 minutes of sleep per day on weekdays can have long-term consequences for body weight and metabolism, a new study finds. The results will be presented Thursday, March 5, at ENDO 2015, the annual meeting of the Endocrine Society in San Diego.
Bayer Inc. and Teva Canada Limited today announced they have entered an agreement regarding Bayer's Adalat XL (nifedipine) 20, 30 and 60 mg product. Effective immediately, Bayer Inc. will supply Adalat XL exclusively to Teva Canada Limited and Teva Canada Limited will become the sole distributor in Canada of brand name Adalat XL product.
Johns Hopkins Kimmel Cancer Center researchers say preliminary studies show that a vaccine made with leukemia cells may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Imatinib mesylate (Gleevec).
› Verified 1 days ago
Tapasya Raavi, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 1235 E Cherokee St, Springfield, MO 65804 Phone: 417-820-2600 | |
Amulya Yadlapalli, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1235 E Cherokee St, Springfield, MO 65804 Phone: 417-820-2600 | |
Dr. Andrew L. Evans, MD Hospitalist Medicare: Not Enrolled in Medicare Practice Location: 1235 E Cherokee St, Springfield, MO 65804 Phone: 417-820-2600 Fax: 417-820-2100 | |
Jean Ye-qiong Guan, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1001 E Primrose St, Springfield, MO 65807 Phone: 417-875-3000 | |
Dr. Kiran Babu Bandaru, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1235 E Cherokee St, Springfield, MO 65804 Phone: 417-820-2600 | |
Mr. Shyam Krishna Thapa, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1235 E Cherokee St, Springfield, MO 65804 Phone: 417-820-2600 |